Press Release

Date: 26th October, 2026 The Manager Listing Compliance Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India Symbol: SAKAR Sub: Press Release - Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026. In continuation of outcome of Board meeting held on October 23, 2026 on the Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026, we attach a copy of Press Release being issued by the Company. This is for information and records. Thanking You, Yours faithfully, FOR, SAKAR HEALTHCARE LIMITED BHARAT SONI COMPANY SECRETARY AND COMPLIANCE OFFICER Sakar Healthcare : Delivers a Strong Quarter, With Revenue Growth of 53% and EBITDA Growth of 114% YoY Ahmedabad, 26th October 2026 :Sakar Healthcare Ltd |NSE: SAKAR, with a research-driven API-integrated EU GMP approved oncology orals and injection manufacturing unit, has announced its unaudited financial results for the quarter & half year ended 30th Sept 2026. Q2 &H1 FY27 Consolidated Financial Performance Particulars (INR Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Lakhs) Revenue from 8,741.61 5,756.04 16038.86 11,029.66 Operations Gross Profit 4,168.05 2,715.40 53% 8,007.08 5,093.78 57% Gross Profit Margin (%) 48% 47% 50% 46% EBITDA 2,434.53 1,135.39 114% 4,559.42 2,405.97 90% EBITDA Margin (%) 28% 20% 28% 22% Profit After Tax 1,130.69 453.98 149% 2159.18 921.11 134% PAT Margin 13% 8% 13% 8% Business Highlights for Q2 & H1FY27 • Executed 69 oncology product contracts, with 45 commercial discussions underway. • Shared 351 dossiers globally, of which 191 have been submitted to regulatory agencies and 22 MAs have been granted • The approved MAs are well dispersed globally: Europe & UK-11, Latin America-6, APAC-4, Canada-1 • Completed 36 EU MA applications, including own16 filings. • Submitted 33 site variations covering 18 cytotoxic molecules of which 11 have been approved in stringent markets of EU and the UK • 33 technology transfer projects for oncology products are underway with 4 partners. • Developed 21 APIs in-house, includes 16 APIs with Written Confirmation, 8 commercialised products, 2 of 7 CEP applications approved and 5 currently in process. • Commercial supplies to domestic & international markets have started from the API-integrated, EU GMP-approved oncology FDF site. • Accord has received 6 more product site variations approval by EMA (total now becomes 8 of 11 molecules) at Sakar’s oncology site along with other 3 site variation approval from MHRA / EMA (for 2-partners in the UK and 1 in Germany). • Coverage has widened covering cancers of breast, lung, prostate, stomach, head & neck, colorectal, ovary, liver, kidney, thyroid, blood, bone-marrow and lymph. Financial Highlights for Q2 & H1 FY27 • Gross Profit: ₹ 4168.05 lakhs in Q2, up 53% YoY . H1 Gross Profit was ₹ 8007.08 lakhs, up 57% YoY. Growth was supported by new oncology approvals and strong demand across geographies. • Operating EBITDA: ₹ 2434.53 lakhs in Q2, up 114% YoY at an 28% margin. H1 EBITDA was ₹4559.42 lakhs, up 90% YoY , at an 28% margin. • Profit After Tax: ₹ 1130.69 lakhs in Q2, up 149% YoY at an 13% margin. H1 PAT was ₹2159.18 lakhs , up 134% , at an 13% margin • Drivers: a better oncology mix, operating leverage and disciplined cost management. Commenting on the Results, Mr. Sanjay Shah, Managing Director said, “Q2 FY27 has been a quarter of meaningful progress for our oncology business, with encouraging developments across regulatory approvals, technology transfers and global market access. These milestones have strengthened our international presence, deepened relationships with global partners and laid a strong foundation for future growth. The commencement of commercial supplies from our EU GMP-approved, API-integrated oncology facility marks an important milestone. Supported by our in-house API capabilities and ongoing technology transfers, we are strengthening our integrated platform, enhancing supply-chain control and expanding our ability to serve regulated markets. Looking ahead, we remain optimistic about the opportunities arising from our expanding oncology portfolio, growing pipeline and international partnerships. We believe these developments will support export growth, improved capacity utilisation and operating efficiencies, positioning Sakar Healthcare for sustainable, long-term growth.” About Sakar HealthCare Limited: Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high- potent oncology products. Sakar’s oncology division at Bavla represents a research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs, underscoring its commitment to innovation and quality. With an extensive global footprint across more than 60 countries, Sakar serves as a trusted partner to multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations. Driven by its vision to deliver world-class healthcare solutions that make lives healthier and more meaningful, Sakar continues to expand its presence across regulated markets through strong R&D capabilities, regulatory excellence, and sustainable manufacturing practices rooted in green chemistry principles. Contact Details Sakar HealthCare Limited Investor Relations: MUFG Intime India Private Limited CIN - L24231GJ2004PLC043861 Mr. Nikunj Seth | Ms. Sejal Bhattar Mr. Dharmesh Thaker nikunj.seth@in.mpms.mufg.com sejal.bhattar@in.mpms.mufg.com info@sakarhealthcare.com Safe Harbor Statement Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections,interest, and other costs.The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.